IoT in Healthcare Market to Reach US$594.5 Bn by 2035 at 23.85% CAGR | Vantage Market Research
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The Global IoT in Healthcare Market is entering a high-impact growth phase as...
Clinical Trial
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
Chairman of Meuhedet, Israel’s third-largest health fundTORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV:...
Olema Oncology Announces Departure of Chief Operating and Financial Officer
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company...
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders Tevogen Board to Evaluate Potential One-Time Special Cash Dividend...
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
FDA sets PDUFA target action date of July 23, 2026FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics,...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the...
Apollo Neuroscience Announces 2025 Year in Review
Community Gains Nearly 144 Million Minutes of Sleep, Wins Best Sleep Wearable of 2025NEW YORK, Jan. 30, 2026 /PRNewswire/ --...
Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development
EXTON, Pa., Jan. 30, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a global Contract Research, Development and Manufacturing Organization (CRDMO),...
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...
Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing...
ALX Oncology Announces Pricing of Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage...
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and...
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”),...
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed...
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to...
Slope and LabConnect Expand Partnership Momentum with Multiple API-Integrated Clinical Trials Launched in Q4 2025
API integration drives adoption among multiple sponsors, unifying data exchange across the biospecimen lifecycle for complex clinical trials.RICHMOND, Va. and...
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to...
Yunu Extends from Site Imaging Standard to Central Review Workflow Leader
New Imaging Automation Delivers a Modern Framework for Central Review & Site Collaboration CARY, NORTH CAROLINA / ACCESS Newswire /...